Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Champions Stability As It Returns To Growth In Q2

Investments In Biosimilars Will Spearhead Financial Goals

Executive Summary

Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.

You may also be interested in...



Gan & Lee Insulins Data Is Boon For Sandoz

Celebrating a “major milestone in the biosimilar clinical development programs,” Gan & Lee has just presented positive data at the recent at the Scientific Sessions of the American Diabetes Association.

Sandoz Launches Pemetrexed In 11 European Countries

Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.

Sandoz To Close Barcelona Plant Under Antibiotics Manufacturing Revamp

Sandoz has shed some light on how it intends to invest €150m into its European antibiotics manufacturing network, while announcing the closure of a plant in Spain to remain “cost-competitive on the global market.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;